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Infection of Indian-origin rhesus macaques by the simian human immunodeficiency virus (SHIV) is considered to be a suitable preclinical
model for directly testing efficacy of vaccine candidates based on the HIV-1 envelope. We used this model for prophylactic vaccination with a
peptide-cocktail comprised of highly conserved HIV-1 envelope sequences immunogenic/antigenic in macaques and humans. Separate groups of
macaques were immunized with the peptide-cocktail by intravenous and subcutaneous routes using autologous dendritic cells (DC) and Freund's
adjuvant, respectively. The vaccine elicited antigen specific IFN-γ-producing cells and T-cell proliferation, but not HIV-neutralizing antibodies.
The vaccinated animals also exhibited efficient cross-clade cytolytic activity against target cells expressing envelope proteins corresponding to
HIV-1 strains representative of multiple clades that increased after intravenous challenge with pathogenic SHIVKU2. Virus-neutralizing antibodies
were either undetectable or present only transiently at low levels in the control as well as vaccinated monkeys after infection. Significant control of
plasma viremia leading to undetectable levels was achieved in majority of vaccinated monkeys compared to mock-vaccinated controls. Monkeys
vaccinated with the peptide-cocktail using autologous DC, compared to Freund's adjuvant, and the mock-vaccinated animals, showed
significantly higher IFN-γ production, higher levels of vaccine-specific IFN-γ producing CD4+ cells and significant control of plasma viremia.
These results support DC-based vaccine delivery and the utility of the conserved HIV-1 envelope peptide-cocktail, capable of priming strong cell-
mediated immunity, for potential inclusion in HIV vaccination strategies.
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The use of the highly active anti-retroviral treatment
(HAART), pioneered approximately a decade ago has made a
strong positive impact on the clinical management of the acquired
immunodeficiency syndrome (AIDS) caused by the human
immunodeficiency virus type 1 (HIV-1) infection. Nevertheless,⁎ Corresponding author. Department of Immunology, The University of Texas
M. D. Anderson Cancer Center, 7455 Fannin, Houston, TX 77030, USA. Fax:
+1 713 563 3276.
E-mail address: jsastry@mdanderson.org (K.J. Sastry).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.08.022the problems associated with drug-related toxicity such as,
resistance development, and economic constraints on populations
that desperately need it, make the development of an effective
vaccine to control HIV-1 infection and prevent development of
AIDS a high priority.
In terms of HIV-specific humoral immunity, adoptive trans-
fer of the neutralizing antibodies was successful in providing
protection against viral challenge in animal models, but only
when the quantity of the antibody employed was high and the
timing of the adoptive transfer was matched close to the
challenge (Baba et al., 2000; Mascola et al., 2003; Robbins et
al., 1995; Gauduin et al., 1997; Poignard et al., 1999). Most of
Table 1
Peptide sequences in the cocktail vaccine and conservation of primary amino
acid sequence among various HIV-1 clades
Peptide Amino acid sequence Conservation
among HIV-1
clades (A–O)
62 (gp41) 586YLRDQQLLGIWG597 84–100%
64 (gp41) 519FLGFLGAAGSTMGAASLTLTVQARQ543 80–100%
J44 (gp41) 549RQQQNNLLRAIEA561 77–92%
104 (gp120) 45VYYGVPVWKEA55 99–100%
111 (gp120) 118LWDQSLKPCVKLT130 93–100%
113 (gp120) 204SVITQACSKVSFE216 92–100%
116 (gp120) 240GTGPCTNVSTVQC252 92–100%
J47 (gp120) 486YKVVKIEPL494 78–100%
Fig. 1. Immunization and challenge scheme for rhesus monkeys in the three
different groups: Control-group, FA-group and DC-group where monkeys were
either mock-vaccinated or immunized with the HIV-1 envelope peptide-cocktail
delivered to rhesus macaques using either the Freund's adjuvant or autologous
DC, respectively. Adult female rhesus macaques (Macaca mulatta) of Indian-
origin between the ages of 8 and 17 years from the specific pathogen-free
breeding colony were uniformly distributed in the three study groups.
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monomeric forms of the envelope protein, gp160 or the surface
subunit gp120, proved ineffective, mainly against primary
patient isolates (Mascola et al., 1996; Barouch and Letvin,
2002). With respect to the HIV-specific cellular immune
responses, there is clear evidence from seminal findings in the
literature for an association with control of primary HIV-1
infection in humans as well as simian immunodeficiency virus
(SIV) infection in macaques, long-term non-progression, and
undetectable virus status in certain individuals belonging to
high-risk groups (Robinson et al., 1999; Kuroda et al., 1999;
McMichael and Rowland-Jones, 2001; Hel et al., 2002; Johnson
et al., 1997; Amara et al., 2001; Letvin et al., 1997; Barouch et
al., 2001; Kostense et al., 2004; Rinaldo et al., 1995; Rowland-
Jones and Douglas, 1993; Rowland-Jones et al., 1995). Several
recent studies evaluating a variety of HIV/SIV vaccine
candidates in primate models revealed protection mediated by
virus-specific helper T cells (TH) and CTL (Nilsson et al., 1998;
Robinson et al., 1999; Migueles et al., 2002; Hel et al., 2002;
Shearer and Clerici, 1998; Clerici et al., 1996). It is important to
note that immune pressure exerted by virus-specific neutralizing
antibodies as well as CTL has been implicated with the
emergence of resistant mutant strains in animal model studies
(Barouch et al., 2002, 2003), but studies connecting the CTL
responses with escape mutants primarily employed single
epitope vaccines or used animals expressing specific MHC
alleles that are prone to promote escape mutations (Barouch et
al., 2002, 2003). Thus, despite high potential for efficacy by the
neutralizing antibodies, it is not clear as to what are the suitable
immunogens and how to develop them, while several animal
models as well as human studies established the potential of
linear sequences from several HIV proteins for priming strong
virus-specific cellular immune responses (Mascola et al., 1996;
Barouch and Letvin, 2002; Kuroda et al., 1999; McMichael and
Rowland-Jones, 2001; Hel et al., 2002; Letvin et al., 1997;
Robinson et al., 1999; Sastry and Arlinghaus, 1991; Nehete et
al., 1993, 1998a,b, 2002, 2005).
Focusing on the potential importance of virus-specific TH
and CTL for protective immunity, we selected eight HIV-1
envelope peptides for selective induction of HIV-specific
cellular immune responses through a series of studies in
multiple animal models (Sastry and Arlinghaus, 1991; Nehete et
al., 1993, 1998a,b, 2002, 2005). A comparison of the primaryamino acid sequence of each of these envelope peptides with
consensus sequences for HIV-1 strains from various clades
(HIV sequence Compendium et al., 2005) revealed a high
degree of homology, ranging between 77% and 100% (Table 1).
Here we report the efficacy of prophylactic vaccination with a
cocktail of these eight HIV-1 envelope peptides in the Indian
origin rhesus macaques (Macaca mulatta) against pathogenic
SHIVKU2 challenge.
Results and discussion
Two different immunization strategies were tested to
determine the effectiveness of the conserved HIV-1 envelope
peptide-cocktail for protection against pathogenic challenge
with SHIVKU2 in Indian-origin rhesus macaques (Fig. 1). One
group of six monkeys received intravenous infusions of
autologous peripheral blood monocyte-derived DC pulsed ex
vivo with the peptide-cocktail (2 ug of each peptide) three times
at monthly intervals (DC-group). Another group of seven
monkeys were injected by the subcutaneous route with the
peptide-cocktail (100 ug of each peptide) emulsified in complete
Freund's adjuvant (CFA) followed by two monthly booster
doses of the peptide-cocktail in incomplete Freund's adjuvant
(IFA) and this group was designated as Freund's adjuvant group
(FA-group). A third group of fivemonkeys was mock vaccinated
once with the CFA and two times with autologous DC, both
without the peptide-cocktail (Control-group).
Cellular immune responses, in terms of IFN-γ producing
CD8+ Tcells specific to all the 8 peptides in the vaccine cocktail
were observed in 5 of 6 monkeys in the DC-group and 5 of 7 in
the FA-group, while the remaining monkeys in each group
exhibited responses to a minimum of 5 peptides (Fig. 2A).
Further, vaccine-specific secretion of IFN-γ (a typical example
for TH1-type cytokines) and IL-6 (a typical example of
inflammatory cytokines) by the PBMC in both the FA-, and
DC-groups of monkeys was evident at week 16 post-
immunization (Fig. 2B). Levels of IL-4, also determined in
these samples, did not show values above the background (data
not shown). Since this time point is 8 weeks after the last
immunization, this analysis provided a potential estimate of the
vaccine-induced memory response in the vaccinated monkeys.
Fig. 2. Induction of antigen-specific cellular immune responses by the HIV-1 envelope peptide-cocktail delivered to rhesus macaques using either the Freund's
adjuvant or autologous DC (FA-group and DC-group, respectively). The peak responses in a total of 105 input CD8+ T cells (isolated from the PBMC of the monkeys)
in the three different groups in terms of IFN-γ producing cells in response to stimulation for 36 h at 37 °C with individual peptides in the peptide-cocktail vaccine were
determined by the ELISPOTassay (A). Induction of antigen-specific cytokine production in the monkeys from the FA-group and the DC-group was determined by the
CBA assay (B). Monkeys in the Control-group did not show production of either of the cytokines in response to stimulation with the peptide-mix (data not shown).
Immunization with the HIV-1 envelope peptide-cocktail primes HIV-1 envelope-specific CTL responses (C). The PBMC obtained from the monkeys in the FA-group
and DC-group were stimulated in vitro for 14 days with the mixture of the eight HIV-1 envelope peptides in the peptide-cocktail vaccine (each peptide at 10 ug/ml final
concentration), and the CTL activity was assayed against autologous B lymphocyte cell lines (B-LCL) infected with recombinant vaccinia virus expressing gp160 from
HIV-1IIIB (vPE160), and the control vaccinia virus (vSC8) in the standard 6 h
51Cr-release methodology. Data for a representative monkey each from the FA-group and
the DC-group are shown.
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showed IFN-γ producing CD8+ T cells (b10 spot forming
cells, SFC) or secretion of IFN-γ or IL-6 (b2 pg/ml) in
response to in vitro stimulation of the corresponding PBMC
by the individual peptides or the peptide-cocktail. However,
innate immune responses indicated by proliferation and
cytokine production upon stimulation with mitogens like
ConA were observed in both the control and vaccinated
monkeys at comparable levels (data not shown). The peptide-
cocktail also primed HIV-1 envelope-specific cytotoxic Tlymphocyte (CTL) responses as shown for a representative
monkey from each of the FA-, and DC-group animals (Fig.
2C). Prior to, as well as at several time points post-
immunization, serum/plasma samples from the vaccinated
monkeys were analyzed for neutralizing antibodies to SHIV-
KU2 and none were observed (titers b10 in all the monkeys),
while a positive control plasma from a SHIVKU2-infected
monkey from a previous unrelated study showed neutralizing
titer of 160 (data not shown). These results indicate that
vaccination with the peptide-cocktail using either autologous
133P.N. Nehete et al. / Virology 370 (2008) 130–141DC or Freund's adjuvant was effective in selectively inducing
antigen-specific cell-mediated immunity without anti-viral
neutralizing antibody responses, and thus enabled us to
specifically test the protective efficacy of HIV-1 envelopeFig. 3. (A) Control of SHIVKU2 infection in monkeys vaccinated with the HIV-1 enve
the Control-group as well as the two vaccine groups (FA-group and DC-group) w
53 weeks post-challenge with SHIVKU2 (10
4 TCID50) by the intravenous route. The
post-challenge and the relative changes subsequently are different in the different
compared to that in the Control-group monkeys. Data in panel B shows significant
Control-group with those in the FA-, and DC-groups combined over the 53 weeks. Lo
in the vaccinated monkeys at weeks 6, 8, 12, 16 and 43 post-challenge (∗).peptide-cocktail-specific cellular immune responses against
pathogenic SHIVKU2-challenge.
At week-25 post-vaccination, monkeys in the control as
well as the two vaccine groups were challenged with SHIVKU2lope peptide-cocktail. Viral loads in plasma samples from individual monkeys in
ere determined by real-time RT-PCR methodology at several time points over
peak viral loads were observed in the monkeys in all the three groups at week 2
groups with majority of the monkeys in the DC-group showing lower levels
differences in the mean plasma viral RNA copy numbers for monkeys in the
g-transformed average viral load changes show significant reduction in viral load
Table 2A
Comparison of the mean plasma viral loads for the monkeys in the two vaccine
groups (FA-group and DC-group together) with that in the Control-group
monkeys over the 53 weeks post-challenge follow-up⁎
Versus Control-group Vaccine-groups
0 week 0 week
2 weeks b0.0001⁎ b0.0001⁎
4 weeks b0.0001⁎ b0.0001⁎
6 weeks b0.0001⁎ b0.0001⁎
8 weeks b0.0001⁎ b0.0001⁎
12 weeks b0.0001⁎ b0.0001⁎
16 weeks b0.0001⁎ 0.0002⁎
24 weeks 0.0013 0.0122
29 weeks 0.0017 0.0103
43 weeks b0.0001⁎ 0.0080
53 weeks 0.0004⁎ 0.0135
⁎ The p-values were compared to 0.001 to determine significance using
Bonferroni method for adjusting multiple comparisons.
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became infected as determined by the real-time RT-PCR
analysis of viral RNA in the plasma samples (Fig. 3A), and
peak virus loads were observed at week-2 post-challenge in
both the control and vaccine groups. However, a comparison
of mean plasma viral RNA copy numbers for monkeys in the
Control-group with those in the two vaccine groups combined
over the 53 weeks of follow-up revealed significantly lower
viral loads in the vaccinated monkeys at weeks 6, 8, 12, 16
and 43 (Fig. 3B). Coinciding with the significant reduction in
viral load in the vaccinated monkeys compared to that in
control monkeys strong increase in CTL responses, specific to
HIV-1 envelope sequences corresponding to 8 different clade
isolates, in addition to HIV-1IIIB, were observed in the
vaccinated monkeys at 16 weeks post-challenge as shown
for a representative monkey for each group in Fig. 4.
Furthermore, as shown in Table 2A, the reduction in viral
load past 2 weeks post-challenge in the vaccinated animals
(the two vaccine groups combined) was very rapid such that
the mean viral load values starting at 24 weeks post-challenge
were not significantly different from the pre-challenge values
at the baseline which is set at 100 viral RNA copy equivalents/
ml of plasma as the lowest sensitivity of the real-time RT-PCR
assay used (the p-values for determining significance were
compared to 0.001 using a repeated measures model along
with the Bonferroni adjustment for multiple comparisons). On
the other hand, the mean viral load values for the Control-
group monkeys were significantly different from the baseline
even at 53 weeks post-challenge suggesting that, despite some
reduction the viral loads did not reach baseline values over
1 year in these animals. These results indicate establishment of
chronic infection in these mock-vaccinated control animals but
not the vaccinated animals. Since significant lowering of
plasma virus loads was observed in the vaccinated monkeys atFig. 4. Cross-clade CTL responses in monkeys vaccinated with the HIV-1
envelope peptide-cocktail. Higher CTL responses, specific to HIV-1 envelope
sequences corresponding to 8 different clade HIV-1 isolates, in addition to HIV-
1IIIB, were observed in the vaccinated monkey compared to that in a control
monkey and the responses in the vaccinated monkey increased substantially
after SHIVKU2-challenge (post-SHIV) compared to levels prior to challenge
(pre-SHIV). The CTL assay was performed as described in Fig. 2C, and the
results are shown for the 25:1 effector to target ratio for a representative monkey
from the control and vaccinated groups.the set point around week 8 post-challenge (Fig. 3B), we also
analyzed for the productively infected cells between weeks 4
and 8 by co-culturing serial dilutions of PBMC from the
monkeys with indicator cells and observed a significant
reduction in the mean TCID50 values for monkeys in both the
FA-group and DC-group compared to that in the Control-
group (Fig. 5). We also compared the mean plasma viral load
in the two vaccine groups separately with the Control-group,
and observed that the DC-group, but not the FA-group,
showed significantly lower values at the set point between
weeks 6 and 12 as well as at week 43 (Fig. 6A). Furthermore,
over the 53-week follow-up the reduction in the mean viralFig. 5. Decrease in cell-associated virus in monkeys vaccinated with the HIV-1
envelope peptide-cocktail. A significant decrease (∗, pb0.05) in cell-associated
virus at the set point (weeks 4–8) was observed in vaccinated animals (FA-group
and DC-group) compared to that in the Control-group. Serial 10-fold dilutions of
PBMC (106 cells/ml) from the monkeys in the different groups were co-cultured
with indicator C8166 cells for 7 days. At the end of the culture period, the cell-
free supernatant from each well was used for determining the amount of
infectious virus by incubating 10-fold serial dilutions with fresh indicator MT4
cells and the 50% tissue culture infectious dose (TCID50) was calculated by the
standard MTT-dye reduction assay. Results shown are average values for the
50% tissue culture infectious dose (TCID50) for 10
6 PBMC form monkeys in
each group.
Fig. 6. Delivery of the HIV-1 envelope peptide-cocktail vaccine using DC is more effective than the Freund's adjuvant for significantly lowering the viral load. The
mean plasma viral RNA copy numbers for monkeys in the Control-group was compared to that in the vaccinated monkeys (the FA-, and DC-groups) over the
53 weeks. The DC-group, but not the FA-group, showed significantly lower mean plasma viral loads (∗) between weeks 6 and 12 and also at week 43 (A). Furthermore,
as shown in panel B, the mean viral load in five monkeys in the DC-group as a sub-group, except J263, that showed similar trends in the viral load changes, showed
significant reduction in the virus load past week 4 post-challenge compared to that in the Control-group at all time points (∗) and also when compared to the FA-group
at week 8 (∗∗). Panel C shows geometric mean values for CD4 cells in the blood for the three different groups with steady decline in the Control-group over the
53 weeks follow-up while stabilization of the CD4 cells was observed in the animals from the two vaccine groups. Panel D shows percentages of monkeys with
undetectable plasma viral loads (using 300 RNA copy equivalents/ml as the lower cut-off value for the sensitivity of the assay) in the three different groups; Control-
group, FA-group and DC-group.
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FA-group and then in the Control-group such that the time
points when the mean viral load values did not significantly
differ from the respective pre-challenge background values
were different for the three groups (Table 2B). For the DC-
Vaccine group this time was 12 weeks, and for the FA-Vaccine
group it was 24 weeks, while for the Control-group the virus
load did not decrease appreciably even at 53 weeks with
respect to baseline scores. Together, these results suggest that,
while delivery of the peptide-cocktail vaccine using the
Freund's adjuvant and DC-based strategies are both effective
in containing the infection by SHIVKU2, only the DC-strategy
yielded protective effect in terms of statistically significant
lowering of the viral load. Among the six monkeys in the DC-
Vaccine group, all except the monkey J263 showed a
significant decline in the viral load, reaching to undetectable
levels, over the 53 weeks of follow-up indicating this monkey
as an outlier in the group (Fig. 3A). Therefore, we analyzed
the data for the rest of the five monkeys, with similar viral
load profiles, as the DC-group (n=5) over the 53 weeks andobserved a highly significant lowering of the viral load
starting as early as week 6 and continuing through week 53
post-challenge, compared to that in the Control-group, and
also at week 8 when compared to the viral load in the FA-
Vaccine group (Fig. 6B).
Infection by SHIVKU2 resulted in some degree of depletion
of CD4 cells in both control and vaccinated monkeys, and the
overall changes in absolute CD4 cell numbers, measured as
geometric mean, were more pronounced in the Control-group
than the vaccinated animals, but the differences did not reach
statistical significance (Fig. 6C). Based on a 300 viral RNA
copy eq/ml value as the lower limit of sensitivity for the real-
time RT-PCR assay the plasma virus was undetectable in one of
the DC-group macaques (L799) as early as week 8, and in 5 of 6
monkeys (83%) by week-43 post-challenge (Fig. 6D). On the
other hand, at the completion of the study (week 53) 4 of the 5
monkeys in the Control-group and 5 of the 7 in the FA-group
were positive for plasma virus loads (measured as N300 viral
RNA copies/ml of the plasma). Similar results were obtained in
assays determining the infected cells measured by co-culturing
Table 2B
Comparison of the changes in the mean plasma viral loads for the monkeys in the
three different experimental groups over the 53 weeks post-challenge follow-up⁎
Versus Control-group FA-group DC-group
0 week 0 week 0 week
2 weeks b0.0001⁎ b0.0001⁎ b0.0001⁎
4 weeks b0.0001⁎ b0.0001⁎ b0.0001⁎
6 weeks b0.0001⁎ b0.0001⁎ b0.0001⁎
8 weeks b0.0001⁎ b0.0001⁎ 0.0003⁎
12 weeks b0.0001⁎ b0.0001⁎ 0.0017
16 weeks b0.0001⁎ 0.0003⁎ 0.0533
24 weeks 0.0013 0.0442 0.1070
29 weeks 0.0017 0.0180 0.1582
43 weeks b0.0001⁎ 0.0180 0.1550
53 weeks 0.0005⁎ 0.0120 0.2197
⁎ The p-values were compared to 0.001 to determine significance using
Bonferroni method for adjusting multiple comparisons.
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strongly suggest that vaccination of monkeys with HIV-1
envelope peptide-cocktail-pulsed DC was effective in control-
ling the virus compared to mock-vaccinated Control-group
animals as well as those vaccinated with the peptide-cocktail
using Freund's adjuvant (FA-group).
For determining the potential correlates of the observed viral
control in the animals vaccinated with the peptide-cocktail, we
analyzed the plasma and PBMC samples for antigen-specific
humoral and cellular immune responses post-challenge. Low
levels of neutralizing antibody responses against the challenge
virus SHIVKU2 (titers b1:40) were observed in four and three
monkeys each in the FA-group and DC-group animals,
respectively at around week 1 post-challenge but did not persist
beyond this time point (data not shown). Similarly, the Control-
group monkeys with persistent viremia and significantly higher
viral loads than the vaccinated animals, also showed low levels
of neutralizing antibodies (titers b1:40) through week-20 post-
challenge (data not shown) similar to earlier reports for this
virus in rhesus macaques (Singh et al., 2005, Joag et al., 1998).
Thus, low to undetectable levels of neutralizing antibodies were
observed post-challenge in all the monkeys with no significant
differences between the different groups. These results, together
with the observation of lack of induction of virus neutralizing
antibodies in any of the vaccinated monkeys (in both FA-, and
DC-groups) prior to challenge, suggest that the observed viral
control in macaques vaccinated with the HIV-1 envelope
peptide-cocktail was independent of anti-HIV humoral
immunity.
Next, we analyzed the peptide-cocktail-specific IFN-γ
producing CD4+ and CD8+ T cells. The viral load set point at
week-8 post-challenge was used as a reference point to compare
responses between the early and late time points (8 and
24 weeks post-challenge, respectively). There was a reduction
in the number of IFN-γ producing CD4+ T cells at week 24 as
compared to that at week 8 in macaques in the Control-group
that coincided with a rebounding trend for the mean viral load
(Fig. 7A). In the FA-group monkeys where the plasma viral
loads did not show significant decrease compared to that in the
Control-group, the number of IFN-γ producing CD4+ T cellsdecreased at week 24 compared to that at week 8. On the other
hand, the number of IFN-γ producing CD4+ T cells increased
between weeks 8 and 24 in the DC-group macaques (Fig. 7A).
We also determined the levels of IL-6 and IFN-γ produced by
PBMC stimulated with the vaccine peptide-cocktail in the
monkeys at week 24 post-challenge and observed production of
IL-6, but not IFN-γ, in majority of monkeys in the Control-
group (Fig. 7B). While monkeys in the FA-group as well as DC-
group showed production of both IL-6 and IFN-γ, on an
average, these two vaccine group monkeys exhibited signifi-
cantly higher amounts of IFN-γ secretion in response to peptide
cocktail stimulation compared to that in mock-vaccinated
Control-group monkeys (Fig. 7C). Furthermore, IFN-γ secre-
tion by the DC-group monkeys was significantly higher than
that by the FA-group monkeys. Production of IL-6 in response
to peptide cocktail stimulation was not significantly different
between the three groups of animals. These results suggesting
potential association between vaccine-specific TH1-type cyto-
kine response (IFN-γ production) and viral control in the DC-
group monkeys are in agreement with previous human studies
that showed a correlation of cellular immune responses
indicated by TH1-type rather than TH2-type cytokine profile
with the control of disease progression in HIV infected
individuals (Shearer and Clerici, 1998; Clerici et al., 1996).
Results from the present investigation suggest the
comparative superiority of DC-based antigen delivery over
the standard animal adjuvant (Freund's) for protective
efficacy of antigen-specific cell-mediated immunity against
SHIV-challenge in the non-human primate model for HIV-
AIDS. These data are in line with reports in the literature that
demonstrated efficiency of the antigen-presenting function of
DC and their potency to deliver peptide-based vaccines
corresponding to tumor antigens (Banchereau et al., 2003; Lu
et al., 2003; Steinman et al., 2003; Pope, 2003; Thurner et al.,
1999; Inaba et al., 1990). In general, effectiveness of DC
against viral infections, in particular for the immunodefi-
ciency viruses, has not been well established. One report
described therapeutic vaccination against SIV in rhesus
macaques of Chinese-origin using autologous DC to deliver
a chemically inactivated virus and showed effectiveness in
significantly reducing viral load by priming both cellular and
humoral immune responses (Lu et al., 2003). In the present
study, we tested a synthetic peptide-cocktail derived from
highly conserved sequences in the HIV-1 envelope protein as
a prophylactic vaccine in rhesus macaques of Indian-origin
against challenge with SHIVKU2 that expresses the HIV-1
envelope proteins and thus vaccine-induced immune
responses controlling the infection are directed against the
HIV portion of the challenge virus. Since these HIV-1
envelope peptides encompass human TH and CTL epitopes,
as shown in our previous studies and also literature reports
(Robinson et al., 1999; Migueles et al., 2002; Hel et al., 2002;
Barouch et al., 2002; Nehete et al., 2002, 2005; Joag et al.,
1998; Hel et al., 2001), the protective efficacy observed in
this model should be of practical value for potentially
including this peptide-cocktail in future clinical testing.
Also, the effectiveness of the HIV-1 envelope peptide-cocktail
137P.N. Nehete et al. / Virology 370 (2008) 130–141in controlling chronic infection by selectively priming cellular
immune responses without virus-neutralizing antibodies
provides further support for the recognized protective role
of antigen-specific cell-mediated immunity.
Despite the general consensus in the scientific community
that the HIV-1 envelope protein is the most important
immunogen for inducing virus-neutralizing antibodies, an
ideal candidate for this is still unavailable (reviewed in
Srivastava et al., 2005). On the other hand, suppression of
CD4+ T cell responses by the HIV-1 envelope protein,
involving several mechanisms including inhibition of prolifera-
tion and induction of anergy, was reported (Kawamura et al.,
2003, Masci et al., 2003, Fernando et al., 2007). Given these
constraints for using the envelope protein as an immunogen for
HIV vaccine development, we propose that the efficiency of the
conserved peptide-cocktail observed in our studies for protec-
tion against chronic infection in the SHIV-rhesus model bodes
well for the inclusion of the peptide-cocktail in a multi-
component HIV vaccine formulation to enrich for virus-specific
cellular immune responses.
Materials and methods
Animals
A total of 18 adult rhesus macaques (M. mulatta) of Indian
origin between the ages of 8 and 17 years, from the specific
pathogen-free breeding colony at the Michael E. Keeling Center
for Comparative Medicine and Research of The University of
Texas MD Anderson Cancer Center, Bastrop TX, were used in
the study. The monkeys were maintained in animal facilities
fully accredited by the Association for Assessment and
Accreditation of Laboratory Animals Care International, and
the study was conducted according to National Institute of
Health Guidelines on Care and Use of Laboratory Animals.
Peptides
Agroup of eight HIV-1 envelope peptides were included in the
cocktail vaccine. Comparison of the primary amino acid
sequences of these peptides to the corresponding consensus
sequences in HIV-1 strains from various clades (HIV sequence
Compendium et al., 2005) revealed a high degree of homology
(Table 1). The antigenic and immunogenic properties of theHIV-1
envelope peptide-cocktail were reported earlier (Sastry and
Arlinghaus, 1991; Nehete et al., 1993; 1998a,b, 2002, 2005;
Lekutis and Letvin, 1997;Wahren et al., 1989). The peptideswere
prepared in the institutional antigen-core facility utilizing FMOC
solid phase chemistry on a PTI Symphony Peptide Synthesizer
(Protein Technologies Inc., Tucson, AZ) and the purity of the
peptides was determined to be N95% by high-pressure liquid
chromatography and was validated by mass spectrometry.
Processing of blood and serum samples
Peripheral venous blood samples were collected in EDTA or
Sodium heparin at different time points pre- and post-immunizations and after challenge with SHIVKU2 (at week 25
with cell-free SHIVKU2, 1×10
4 TCID50). Before the separation
of peripheral blood mononuclear cells (PBMC) from the blood
samples, plasma was separated and stored immediately at
−80 °C. The PBMC were prepared from the blood samples by
the standard ficoll-hypaque density-gradient centrifugation and
used for virus isolation and various immune assays.
Preparation of dendritic cells (DC) from PBMC
DC were prepared from macaque PBMC samples by the
standard protocol (O'Doherty et al., 1997; Nehete et al., 2003)
involving separation of plastic adherent monocyte population and
cytokine-mediated differentiation during 7-day culturing with
GM-CSF (1000 units/ml, Sargramostim Leukine, Immunex,
Seattle WA) and IL-4 (1000 units/ml, R&D System, Minneapolis,
MN) at 37 °C. On day 6 of incubation, the cells with dendritic
morphologywere collected in 1ml of cytokinemedium in 24-well
tissue culture plates and pulsedwith the peptidemixture consisting
of 2 ug each of the peptides along with maturation using TNF-α
(1000 units/ml) by incubating overnight at 37 °C. Subsequently,
the mature DCwere washed and used either for in vitro functional
assays or for immunization of the monkeys. On an average 1–
3×106 mature DC were obtained using PBMC from 20 ml of
blood (1–3% of PBMC), similar to the yields reported in the
literature (O'Doherty et al., 1997; Nehete et al., 2003). Phenotypic
analyses were performed to ascertain expression of DC surface
markers (Lin−, HLA-DR+, CD83+, CD86+ and CD11c+) by flow
cytometry. On an average, a dose of 1×106 mature DC pulsed
with the peptide cocktail was used for each infusion.
ELISPOT assay for detecting antigen-specific IFN-γ producing
cells
Freshly prepared PBMC were used for isolating CD4+ and
CD8+ cells by positive selection usingmagnetic beads according
to manufacturer instructions (Dynal Inc. Lake Success, NY) and
stimulated with peptide-pulsed autologous monocyte-derived
DC for the IFN-γ ELISPOTassay as described earlier (Nehete et
al., 2003). Peptides from the vaccine cocktail were used either
individually or as mixtures along with an unrelated control
peptide (from human papillioma virus, HPV) at 10 μg/ml final
concentration, and Con A (5 μg/ml) was used as positive control
reagent. The cells (1×105) were seeded in duplicate wells of 96-
well plates (polyvinylidene difluoride backed plates, MAIP S
45,Millipore, Bedford,MA) and incubated in the presence of the
various antigens for 36 h at 37 °C. Subsequently, the cells were
removed and the wells were thoroughly washed with PBS before
incubation with 100 μl of biotynylated secondary antibody to
IFN-γ (detection antibody) for 3 h at 37 °C followed by avidine
peroxidase treatment for another 30 min. Spots representing
individual cells secreting IFN-γ were developed using freshly
prepared substrate (0.3 mg/ml of 3-amino-9-ethyl-carbazole) in
0.1 M sodium acetate buffer, containing 0.015% hydrogen
peroxide. Plates were washed to stop color development, and the
filters were sent to an independent agency (Zellnet Consulting,
New Jersey, NJ) where the spots were counted using the KS-
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Fig. 7. Monkeys immunized with autologous DC pulsed with the HIV-1
envelope peptide-cocktail exhibit strong TH1 responses and control of viremia.
The numbers of IFN-γ-producing cells in a total of 105 input CD4+ T cells
(isolated from the PBMC), in terms of IFN-γ spot forming cells (SFC) were
analyzed by the ELISPOTassay at the early and late time points (8 and 24 weeks
post-challenge, respectively) as described in the Materials and methods section.
Panel A shows the average numbers of IFN-γ-producing CD4+ T cells with a
steep decrease between weeks 8 and 24 time points for the monkeys in the
Control-group and FA-group where significant drop in viral loads were not
observed, but they increased over the same period in the DC-group where the
viral loads decreased significantly. Panel B shows the levels of IFN-γ and IL-6
produced by PBMC collected at week 24 post-challenge from the individual
monkeys in the three different groups in response to stimulation with the mixture
of the peptides in the vaccine-cocktail using the Cytometric Bead Array assay as
described in the Materials and methods section. Monkeys in the Control-group
predominantly showed production of IL-6 but not IFN-γ. Panel C shows
comparison of average values for the levels of IFN-γ and IL-6 produced, in
response to stimulation with the mixture of the peptides in the vaccine-cocktail,
in the three different groups. Significantly higher amount of IFN-γ production
(pb0.05) was observed for monkeys in the FA-group and DC-group compared
to that in the Control-group (∗), as well as significantly higher amounts in the
DC-group compared to the FA-group (∗∗).
139P.N. Nehete et al. / Virology 370 (2008) 130–141ELISPOT automatic system (Carl Zeiss, Inc. Thornwood, NY)
for the quantitative analysis of the number of IFN-γ spot forming
cells (SFC). The responses in terms of IFN-γ spot forming cells
(SFC) for 105 total input CD8+ T cells were determined for
individual monkeys after subtracting background values of cells
cultured in the medium. The cut off value for determining the
positive response in the assay is defined as a minimum of 10
spots that is twice the number observed in cells cultured in the
medium.
Cytokine assay
Aliquots of the PBMC (1×105) from the different
monkeys were cultured in the presence of the peptide mixture
(each peptide at 10 μg/ml final concentration), in complete
RPMI-1640 medium, in triplicate wells of 96-well U-bottom
plates for 36 h at 37 °C. Supernatants (100 μl) were removed
from each well after centrifuging the plates, and stored frozen
at −70 °C. At the time of assay, the samples were thawed and
assayed for IFN-γ and IL-6, using the BD Cytometric Bead
Array (CBA) kit (Beckton Dickinson, San Jose, CA). Culture
medium and Con A (5 μg/ml) were used as negative andpositive controls respectively. The antibodies used exhibit
cross reactivity with rhesus blood cells as reported by the
manufacturer.
CTL assay
Antigen-specific CTL activity was measured from isolated
and stimulated PBMC using the standard 6-h radioactive
chromium (51Cr)-release assay as described before (Nehete et
al., 2002, 2005). Briefly, isolated PBMC were stimulated for
two rounds on days 0 and 7 with paraformaldehyde-fixed
autologous B-lymphoid cell lines (B-LCL) that were loaded
with the peptide mixture. The target cells for the assay were
prepared by infecting separate aliquots of the autologous B-
LCL with recombinant vaccinia viruses expressing the gp160
envelope protein corresponding to different geographical
clade isolates of HIV-1 and the control vaccinia virus
(vSC8), obtained from the AIDS Research and Reference
Reagent Program, Rockville, MD. Target cell lysis was
measured at various effector-to-target ratios. In some experi-
ments, unlabeled K562 or autologous B-LCL cells were used
to reduce the background natural killer cell-mediated lysis.
After 6 h incubation, 100 μl of supernatant was collected
from each well and the amount of 51Cr released was
determined using the γ-counter. To account for the maximum
release, the cells were incubated with 5% Triton X-100.
Spontaneous release was determined from target cells
incubated without added effector cells. The % of specific
lysis was calculated by the following formula: % Specific
lysis= (experimental release− spontaneous release) / (maximum
release− spontaneous release)×100.
Viral load determination
Viral copy numbers in EDTA plasma samples from each
monkey were monitored by detecting SHIVKU2 RNA using
real-time RT-PCR analyses performed at the NIH core facility
(run by Dr. Jeff Lifson's group). The threshold sensitivity of the
assay is between 100 and 300 viral RNA copy-equivalents/ml of
plasma, and the inter-assay variation is b25% (coefficient of
variation).
Determination of cell associated virus
The PBMC collected from the control and vaccinated
macaques at three separate time points were assessed for cell-
associated virus by infectious center assay (ICA) as described
earlier (Nehete et al., 2002, 2005). Briefly, 10-fold dilutions of
PBMC (ranging between 1 and 105 cells) were co-cultured with
106 indicator C8166 cells (four wells/per dilution) in 24-well
tissue culture plates for 7 days and the cytopathic effect was
noted. At the end of the culture period, the cell-free supernatant
from each well was used for determining the amount of
infectious virus by incubating 10-fold serial dilutions with fresh
indicator MT4 cells and the 50% tissue culture infectious dose
(TCID50) was calculated by the standard MTT-dye reduction
assay.
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Plasma samples collected from heparin blood of monkeys at
the beginning of the study and at different time points before
and after SHIV-challenge were assayed using the protocol
described earlier (Nehete et al., 2002, 2005). Briefly, serial two-
fold dilutions of heat-inactivated plasma in RPMI were
prepared in duplicate wells of 24-well plates and mixed with
SHIVKU2 (20 TCID50). The plates were incubated for 2 h at
37 °C followed by the addition of 104 indicator MAGI cells
(HeLa cells expressing β-galacotosidase and human CD4
obtained from the AIDS Research and Reference Reagent
Program, Rockville, MD). Plates were observed for infected
cells (blue colored cells expressing β-galactosidase) 3 days
later, and the wells were scored individually. Pre-immunization
plasma was used as negative control, and plasma from a SHIV-
infected monkey from a previous unrelated study was used as
positive control. The neutralization titer was calculated as the
plasma dilution at which the numbers of blue cells were equal to
that in control wells where cells were infected with virus
pretreated with pre-immune plasma or control uninfected
monkey plasma. In general titers of b10, obtained with pre-
immune serum samples, were considered background values.
Statistical analysis
Data for the viral loads in the monkeys from all three groups
(Control-group, FA-group and DC-group) was analyzed using a
repeated measures model to evaluate the effects of the two
different vaccination strategies, in comparison to the mock-
vaccinated control group, using changes in the viral RNA
copies at different time points. The data were standardized using
logarithm transformation, in order to stabilize the variances, for
all subsequent analyses. To determine the significance, the p-
values were compared after factoring in the Bonferroni
correction for multiple comparisons. Additionally, standard
two-sided t-tests with a p-value set for 0.05 were utilized for
determining the differences in the amounts of cell-associated
virus (using infectious center assay), cytokine producing cells
(using ELISPOT assay) and secretion of cytokines (using
cytokine bead array method) at a single time point between the
control and each of the vaccine groups separately.
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